AstraZeneca signs up Regulus in microRNA deal
This article was originally published in Scrip
Regulus Therapeutics, a microRNA-focused drug developer, has added to its impressive roster of pharmaceutical partners by signing a new deal with AstraZeneca.
You may also be interested in...
The micro-RNA-focused biotech believes the jaundice seen with HCV candidate RG-101 was specific to the drug, not the target or delivery system, but is switching focus to other promising programs, such RG-012 for Alport syndrome.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.